Pneumococcal serotypes in children in 4 European countries.

After heptavalent pneumococcal conjugate vaccine (PCV7) was marketed in France, Spain, Belgium, and England and Wales (United Kingdom), invasive disease from non-PCV7 serotypes (NVT) increased. Adjusted serotype-specific incidences among children <15 years of age were compared between 1999-2002 (prevaccine) and 2005-2006 (postmarketing). Vaccine coverage increased to approximately 32%-48% in France, Spain, and Belgium but remained <1% in England and Wales. Serotype 1 incidence rose in all age groups and countries (incidence rate ratio [IRR] 1.3-4.2; p<0.004), independently of PCV7 use, but incidence of serotypes 7F and 19A increased most in France, Spain, and Belgium (IRR 1.9-16.9 in children <5 years; p<0.001), where PCV7 coverage was greater. Vaccine-induced replacement of PCV7 serotypes possibly contributed to NVT increases, as did secular trends. New vaccines targeting these serotypes are available, but serotype dynamics needs further exploration that accounts for underreporting and prevaccine trends.

[1]  Herman Goossens,et al.  European Surveillance of Antimicrobial Consumption (ESAC) , 2011, Drugs.

[2]  Matthew R Moore,et al.  A dynamic model of pneumococcal infection in the United States: implications for prevention through vaccination. , 2010, Vaccine.

[3]  Jla,et al.  Dynamic Changes of Pneumococcal Serotypes after Introduction of PCV7 in Belgium , 2009 .

[4]  R. Dagan.  Serotype replacement in perspective. , 2009, Vaccine.

[5]  M. P. van der Linden,et al.  Reduction in the incidence of invasive pneumococcal disease after general vaccination with 7-valent pneumococcal conjugate vaccine in Germany. , 2009, Vaccine.

[6]  D. Greenberg,et al.  Introduction and proliferation of multidrug-resistant Streptococcus pneumoniae serotype 19A clones that cause acute otitis media in an unvaccinated population. , 2009, The Journal of infectious diseases.

[7]  G. Hanquet,et al.  Temporal Trends of Invasive Streptococcus pneumoniae Serotypes and Antimicrobial Resistance Patterns in Spain from 1979 to 2007 , 2009, Journal of Clinical Microbiology.

[8]  D. Livermore,et al.  Non-susceptibility trends and serotype distributions among Streptococcus pneumoniae from community-acquired respiratory tract infections and from bacteraemias in the UK and Ireland, 1999 to 2007. , 2008, The Journal of antimicrobial chemotherapy.

[9]  C. Muñoz-Almagro,et al.  Identification of pneumococcal serotypes from culture-negative clinical specimens by novel real-time PCR. , 2008, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.

[10]  D. Levy-bruhl,et al.  Impact of infant pneumococcal vaccination on invasive pneumococcal diseases in France, 2001-2006. , 2008, Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin.

[11]  M. P. van der Linden,et al.  Childhood invasive pneumococcal disease in Germany between 1997 and 2003: variability in incidence and serotype distribution in absence of general pneumococcal conjugate vaccination. , 2008, Vaccine.

[12]  D. Caugant,et al.  Effectiveness of a 2+1 dose schedule pneumococcal conjugate vaccination programme on invasive pneumococcal disease among children in Norway. , 2008, Vaccine.

[13]  S. Kim,et al.  Streptococcus pneumoniae Serotype 19A in Children, South Korea , 2008, Emerging infectious diseases.

[14]  W. Hanage.  Serotype-specific problems associated with pneumococcal conjugate vaccination. , 2008, Future microbiology.

[15]  C. Muñoz-Almagro,et al.  Emergence of invasive pneumococcal disease caused by nonvaccine serotypes in the era of 7-valent conjugate vaccine. , 2008, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[16]  W. Peetermans,et al.  Pneumococcal bacteraemia in Belgium (1994 2004): the pre-conjugate vaccine era. , 2007, The Journal of antimicrobial chemotherapy.

[17]  W. Schaffner,et al.  Incidence of pneumococcal disease due to non-pneumococcal conjugate vaccine (PCV7) serotypes in the United States during the era of widespread PCV7 vaccination, 1998-2004. , 2007, The Journal of infectious diseases.

[18]  W. Hanage.  Serotype replacement in invasive pneumococcal disease: where do we go from here? , 2007, The Journal of infectious diseases.

[19]  R. Pebody,et al.  Morbidity and mortality of pneumococcal meningitis and serotypes of causative strains prior to introduction of the 7-valent conjugant pneumococcal vaccine in England. , 2007, The Journal of infection.

[20]  C. Ihekweazu,et al.  Trends in incidence of pneumococcal disease before introduction of conjugate vaccine: South West England, 1996–2005 , 2007, Epidemiology and Infection.

[21]  M. Caniça,et al.  Invasive pneumococcal disease in Portugal prior to and after the introduction of pneumococcal heptavalent conjugate vaccine. , 2007, FEMS immunology and medical microbiology.

[22]  J. Castilla,et al.  Effectiveness of the 7-valent pneumococcal conjugate vaccine: a population-based case-control study. , 2007, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[23]  L. Hammitt,et al.  Invasive pneumococcal disease caused by nonvaccine serotypes among alaska native children with high levels of 7-valent pneumococcal conjugate vaccine coverage. , 2007, JAMA.

[24]  R. Cohen,et al.  Impact of Pneumococcal Conjugate Vaccine and of Reduction of Antibiotic Use on Nasopharyngeal Carriage of Nonsusceptible Pneumococci in Children With Acute Otitis Media , 2006, The Pediatric infectious disease journal.

[25]  J. Verhaegen,et al.  Epidemiologic Features of Invasive Pneumococcal Disease in Belgian Children: Passive Surveillance Is Not Enough , 2006, Pediatrics.

[26]  R. Pebody,et al.  Susceptibility of pneumococci causing meningitis in England and Wales to first-line antimicrobial agents, 2001-2004. , 2005, Journal of Antimicrobial Chemotherapy.

[27]  A. Schuchat,et al.  Decline in invasive pneumococcal disease after the introduction of protein-polysaccharide conjugate vaccine. , 2003, The New England journal of medicine.

[28]  D. Feikin,et al.  Historical changes in pneumococcal serogroup distribution: implications for the era of pneumococcal conjugate vaccines. , 2002, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[29]  H. Konradsen,et al.  Invasive Pneumococcal Infections in Denmark from 1995 to 1999: Epidemiology, Serotypes, and Resistance , 2002, Clinical and Vaccine Immunology.

[30]  J. Zhou,et al.  Dynamics of penicillin-susceptible clones in invasive pneumococcal disease. , 2001, The Journal of infectious diseases.

[31]  G. Siber,et al.  Geographical differences in invasive pneumococcal disease rates and serotype frequency in young children , 2001, The Lancet.

[32]  B. Henriques Normark, Å. Örtqvist, M. Kalin, B. Ol.  Changes in Serotype Distribution may Hamper Efficacy of Pneumococcal Conjugate Vaccines in Children , 2001 .

[33]  I. Jado,et al.  Dot blot assay for the serotyping of pneumococci , 1997, Journal of clinical microbiology.

[34]  A. Ortqvist,et al.  Changes in serotype distribution may hamper efficacy of pneumococcal conjugate vaccines in children. , 2001, Scandinavian journal of infectious diseases.

[35]  M. Ferraro.  Performance standards for antimicrobial susceptibility testing , 2001 .

[36]  L. Harrison,et al.  Active bacterial core surveillance of the emerging infections program network. , 2001, Emerging infectious diseases.